Targeting metabolic mechanisms to overcome temozolomide resistance in glioblastoma
Discover Oncology · 12.02.2026 · 17 (1)
DOI: 10.1007/s12672-026-04572-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 12.02.2026. Verfasst von Chengrui Yan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Center for Malignant Brain Tumors, Peking Union Medical College Hospital, National Glioma MDT Alliance, Chinese Academy o…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, Peking Union Medical College Hospital Talent Cultivation Program (Category C).
Abstract (Originalsprache)
Temozolomide (TMZ) resistance remains a major clinical obstacle in the treatment of glioblastoma (GBM), a highly aggressive brain tumor with poor prognosis. Growing evidence showed that metabolic reprogramming contributed to TMZ resistance and offered new avenues for intervention. This review comprehensively summarizes resistance-associated changes across three key areas – glycolysis, redox homeostasis, and lipid metabolism in TMZ-resistant GBM. The resistant cells tend to display enhanced glycolytic flux, with upregulation of glucose transporter and glycolysis enzymes. To counteract TMZ-induced oxidative stress, antioxidant systems are activated. Lipid metabolism is also extensively rewired, involving increased fatty acid oxidation, de novo lipogenesis, steroid hormone synthesis, and prostaglandin E₂-mediated signaling, along with a decreased ceramide level. Emerging preclinical research investigated therapeutic strategies targeting resistance-associated metabolic changes to reverse TMZ efficacy. Though preclinical research showed encouraging results, further validation in clinical settings is still needed. A deeper understanding of context-specific metabolic adaptations helps better elucidate the role of metabolism in resistance and to identify therapeutic opportunities with greater clinical translational potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Center for Malignant Brain Tumors, Peking Union Medical College Hospital, National Glioma MDT Alliance, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730,…
- Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Förderung
- CAMS Innovation Fund for Medical Sciences
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- Peking Union Medical College Hospital Talent Cultivation Program (Category C)
- Beijing Science And Technology Innovation Medical Development Foundation
- Beijing Municipal Natural Science Foundation
Zitieren
APA
Yan, C., Ge, Y., Hu, Z., & Ma, W. (2026). Targeting metabolic mechanisms to overcome temozolomide resistance in glioblastoma. Discover Oncology, 17(1). https://doi.org/10.1007/s12672-026-04572-6
Vancouver
Yan C, Ge Y, Hu Z, Ma W. Targeting metabolic mechanisms to overcome temozolomide resistance in glioblastoma. Discover Oncology. 2026;17(1). doi:10.1007/s12672-026-04572-6
BibTeX
@article{Yan2026,
author = {Yan, Chengrui and Ge, Yulu and Hu, Zhan and Ma, Wenbin},
title = {Targeting metabolic mechanisms to overcome temozolomide resistance in glioblastoma},
journal = {Discover Oncology},
year = {2026},
volume = {17},
number = {1},
doi = {10.1007/s12672-026-04572-6}
}
EUVIMED